Global Partners LP
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Eric Slifka
- Full Time Employees
- 4,700
- Sector
- Energy
- Industry
- Oil & Gas Midstream
- Address
- 800 South Street Waltham MA United States of America 02454-9161
- IPO Date
- Oct 4, 2005
- CIK
- 0001323468
- Website
- globalp.com
- Similar Companies
- Business
- Global Partners LP Global Partners LP (NYSE: GLP), a master limited partnership founded in 2005 with roots tracing back to 1933, serves as a leading midstream logistics and marketing company headquartered in Waltham, Massachusetts. The company engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates including diesel and heating oil, residual oil, renewable fuels such as biodiesel and ethanol, crude oil, propane, natural gas, and bunker fuel to wholesalers, retailers, gasoline station operators, sub-jobbers, commercial and industrial end-users, and public sector customers; it operates through three segments—Wholesale, which supplies branded and unbranded gasoline, home heating oil, kerosene, and residual oil via railcars, barges, trucks, and pipelines; Gasoline Distribution and Station Operations (GDSO), which distributes fuels to over 1,700 owned, leased, or supplied retail locations featuring convenience stores, prepared foods, car washes, lottery, and ATM services primarily across Northeast states, the Mid-Atlantic, and Texas; and Commercial, which delivers custom-blended fuels and energy products with a focus on the Northeast U.S. Global maintains dedicated storage at 54 liquid energy terminals connected to rail, pipeline, and marine assets spanning from Maine to Florida and into the U.S. Gulf States, while offering low-carbon solutions like GlobalGLO to support carbon footprint reduction. In recent developments, Global Partners LP completed the acquisition of a 959,730-barrel liquid energy terminal in East Providence, Rhode Island, from ExxonMobil Oil Corporation in November 2024, enhancing gasoline infrastructure, truck rack capacity, and supply optionality for its Northeast retail and marketing operations while adding surplus real estate for future development; the company also issued $450 million in senior unsecured notes due 2033 in June 2025, co-issued with GLP Finance Corp. and guaranteed by subsidiaries, to bolster its capital structure amid ongoing terminal expansions and diversification into renewable fuels.
Company News
3 Top Oil & Gas MLPs to Consider with Dividend Yields Above 5%
3 Reasons Why Growth Investors Shouldn't Overlook Global Partners (GLP)
Lilly's Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell'
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance
Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly's GLP-1 Drugs
GLP-1 weight loss drugs effective even at low starter doses
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly's Weight-Loss Boom Hitting an Insurance Wall?
Should Value Investors Buy Global Partners (GLP) Stock?
Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren't the Reason
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs?
GLP-1 maker hit with 'sell' rating as 2027 revenue cliff fears mount
IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers
Lilly's GLP-1 pill hits UK pharmacies as US battle with Novo intensifies
Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030